Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ensysce Biosciences (ENSC)
NASDAQ:ENSC
RESEARCH TOOLSreports
Ensysce Biosciences (ENSC) Stock Price & Analysis
126 Followers
ENSC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.53 - $7.20
Previous Close$0.57
Volume82.92K
Average Volume (3M)194.21K
Market Cap
$4.15M
Enterprise Value$3.55M
Total Cash (Recent Filing)$1.12M
Total Debt (Recent Filing)$854.70K
Price to Earnings (P/E)>-0.1
Beta1.22
Next Earnings
May 09, 2024EPS Estimate
-$0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-151.28
Shares Outstanding7,329,172
10 Day Avg. Volume81,709
30 Day Avg. Volume194,211
Standard Deviation0.36
R-Squared0.01
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)-12.74
Price to Sales (P/S)1.86
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit1.59
Enterprise Value/Ebitda-1.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ensysce Biosciences News
PremiumCompany Announcements
Ensysce Biosciences Secures Funding and Expands Shareholder Value
Ownership Overview
57.99%
Insiders
0.50% Mutual Funds
1.57% Other Institutional Investors
39.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $0.53 and its highest was $7.20 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Currently, no data Available
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is May 09, 2024 which is yesterday.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on Mar 15, 2024. The company reported -$1.13 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.26.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate is -$0.9.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 7,329,172 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$1.13 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went up 5.333%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Among the largest hedge funds holding Ensysce Biosciences’s share is HG Vora Capital Management, LLC. It holds Ensysce Biosciences’s shares valued at N/A.
---
Ensysce Biosciences Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 10.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-53.98%
Trailing 12-Months
Company Description
Ensysce Biosciences
Leisure Acquisition Corp. operates as blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on the location-based leisure sector and leisure-related businesses. Leisure Acquisition was founded on September 11, 2017 and is headquartered in New York, NY.
---
ENSC Stock 12 Month Forecast
Average Price Target
―Technical Analysis
XTL Biopharmaceuticals Ltd. Sponsored ADR
―
Bio-Path Holdings
―
ADMA Biologics
―
BioCryst
―
Best Analysts Covering ENSC
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-68.45%
reiterated a buy rating 8 months ago
Copying Boobalan Pachaiyappan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -68.45% per trade.
---